Dr Mayte Coiras is an expert in immunopathology. Dr Coiras is a tenured scientist at the Immunopathology Unit of the National Center of Microbiology (Instituto de Salud Carlos III). She established in 2016 the first collaboration with hematologists from different hospitals in Madrid (Spain) to initiate and study the antileukemic and antiviral mechanisms developed by treatment with tyrosine kinase inhibitors on patients with chronic myeloid leukemia. Another major research line for Dr Coiras is the study of new strategies to achieve an HIV cure through the analysis of the therapeutic potential of tyrosine kinease inhibitors such as dasatinib to interfere with HIV infection, proviral reactivation, and reservoir replenishment. Lately, Dr Coiras developed an interest in contributing to the understanding the immunopathological mechanisms of SARS-CoV-2 infection during COVID-19 pandemic and she has published several studies about this topic. Dr Coiras has h-index 19 with more than 60 publications in peer-reviewed journals with a high impact factor. She is also principal investigator of 13 research projects since 2008 (mostly funded in competitive calls by the Spanish Ministry of Science and Innovation and the U.S. National Institutes of Health (NIH)) and she received an award for The Best Young Investigator from the Ministry of Health and the Foundation for Research and Prevention of AIDS in Spain (FIPSE) in 2011.
Dr Mayte Coiras is an expert in immunopathology. Dr Coiras is a tenured scientist at the Immunopathology Unit of the National Center of Microbiology (Instituto de Salud Carlos III). She established in 2016 the first collaboration with hematologists from different hospitals in Madrid (Spain) to initiate and study the antileukemic and antiviral mechanisms developed by treatment with tyrosine kinase inhibitors on patients with chronic myeloid leukemia. Another major research line for Dr Coiras is the study of new strategies to achieve an HIV cure through the analysis of the therapeutic potential of tyrosine kinease inhibitors such as dasatinib to interfere with HIV infection, proviral reactivation, and reservoir replenishment. Lately, Dr Coiras developed an interest in contributing to the understanding the immunopathological mechanisms of SARS-CoV-2 infection during COVID-19 pandemic and she has published several studies about this topic. Dr Coiras has h-index 19 with more than 60 publications in peer-reviewed journals with a high impact factor. She is also principal investigator of 13 research projects since 2008 (mostly funded in competitive calls by the Spanish Ministry of Science and Innovation and the U.S. National Institutes of Health (NIH)) and she received an award for The Best Young Investigator from the Ministry of Health and the Foundation for Research and Prevention of AIDS in Spain (FIPSE) in 2011.